We have studied factor IXa binding and factor X activation with normal platelets and with platelets obtained from a patient with a bleeding disorder and an isolated deficiency of platelet procoagulant activity termed Scott syndrome. In the absence of factor VIIIa and factor X, normal, thrombin-treated platelets exposed 560±35 sites for factor IXa with a Kd of 2.75±0.27 mM, compared with 461±60 sites per patient platelet with Kd of 3.2±0.33 nM. The addition of factor VIIIa and factor X resulted in a decrease in the Kd for normal platelets to 0.68 nM but had no effect on the Kd for patient platelets. The concentrations of factor IXa required for half-maximal rates of factor X activation for normal (0.52 nM) and patient platelets (2.5 nM) were similar to those determined from equilibrium binding studies. Kinetic parameters for factor X activation by factor IXa showed that the K. and k,1 were identical for normal and patient platelets in the absence of factor VIlla. In the presence of factor VIIIa, and k,,1, for patient platelets (163 min-') was only 33% of that for normal platelets (491 min-')-This result can be explained by the difference in affinity for factor IXa between normal and patient platelets in the presence of factor VIIIa, suggesting impaired factor VIIIa binding to Scott syndrome platelets.
Introduction
Platelets promote the catalysis of two sequential, calcium-dependent reactions in blood coagulation: the activation of factor X by a complex of factor IXa and factor Vllla (1) (2) (3) (4) (5) (6) and the conversion of prothrombin to thrombin by a complex of factor Xa and factor Va (7) (8) (9) (10) (11) (12) . The contribution of platelets to prothrombin activation is receptor mediated, since platelets possess specific, high-affinity, saturable binding sites for factor Xa (7, 10) and factors V and Va (11, 12) and receptor occupancy is closely correlated with rates of prothrombin activation (7) (8) (9) (10) (11) (12) . Recently we have demonstrated that activated human platelets also have specific, saturable receptors for factor IXa involved in factor X activation (13) . The presence of factor VIII, which also binds to specific, high-affinity sites on activated platelets (14) , together with factor X, increases fivefold the affinity of factor IXa binding to activated platelets (13) . In order to investigate in more detail the mechanism of factor X activation by platelet-bound factor IXa, we have carned out studies of factor IXa binding and factor X, activation with normal platelets and with platelets obtained from a patient with a bleeding disorder termed Scott syndrome (15, 16) . These platelets, which have previously been shown to have an isolated deficiency of platelet procoagulant activity (15) , lack factor Xa binding sites (17) and are deficient both in their capacity to promote prothrombin activation (17, 18) and factor X activation (18) and to expose phosphatidylserine at the outer surface of stimulated platelets ( 18) .
Methods
Platelets. Gel-filtered platelets were isolated as described previously (13) . The patient, MS, who has been reported in detail by Weiss et al. (15) , is a 45-yr-old woman with a moderate bleeding disorder now referred to as Scott syndrome (16) . She visited Philadelphia and her platelets were studied on three separate occasions in direct comparison with control platelets adjusted to the same platelet count.
Purification of proteins. Factor IX (333 U/mg) was purified to apparent homogeneity from human plasma by immunoaffinity chromatography and was converted to factor IXa by incubation with purified factor XIa as previously described (13) . Factor IX was radiolabeled with 125I by the Iodogen method (19), as previously described (13) . The majority ofthe free 125I was then separated from the protein by passage through a l-ml G-25 column (20), and the labeled protein was further dialyzed in the presence of ovalbumin (1 mg/ml). Purified human factor X had a specific activity of 225 U/mg and appeared as a single band with an apparent molecular weight of 72,000 on nonreduced SDS gels as reported previously (13) . Purified human factor VIII, kindly provided by Dr. J. E. Brown (Cutter Biological, Miles, Inc., Berkeley, CA), had a specific activity of 1,850 U/mg, was devoid ofvon Willebrand factor antigen, and consisted ofprotein bands with molecular masses of 230, 92, 80, and 40 kD on SDS-PAGE as previously described (13) . The factor VIII activity was increased 38-fold in 1 min by incubation of the protein with 0.05 U/ml of human a-thrombin, was stable for 3 min and remained within 50% of its maximal activity for at least 10 min, during which time all binding and factor X activation experiments were completed.
Binding experiments. These were carried out as reported in detail earlier (13) in triplicate on three separate occasions using platelets obtained from MS and from three separate normal donors. Saturation binding data were analyzed by the method of Scitchard (21) as previously reported using linear regression analysis and assuming a single class of binding sites.
Measurement ofrates offactorXaformation. Activation offactor X by factor IXa in the presence of stimulated platelets either in the presence or absence of factor VIIIa (for further experimental condi-tions, see figure legends) was monitored in incubation mixtures containing platelets, factor IXa, CaC12, and thrombin at 37°C for 10 min in a buffer containing 50 mM Tris-HCI, 175 mM NaCI, and 0.5 mg/ml human serum albumin (pH 7.4). Excess thrombin was neutralized with 50 nM D-Phe-Pro-Arg-chloromethylketone (PPACK,' Calbiochem-Behring Corp., San Diego, CA) prior to the addition of factor VIIIa and factor X to the reaction mixture. After 3 min (presence of factor VIIIa) or 10 min (absence of factor VIIIa) at 37°C 10 mM EDTA was added to prevent further activation of factor X by factor IXa. During this time period rates of factor Xa formation were linear. The release ofp-nitroanilide from 0.5 mM S2337 (factor Xa-specific chromogenic substrate from AB Kabi Diagnostica, Stockholm, Sweden) by factor Xa was followed for 10 min, during which period the rates ofcleavage of S2337 were linear. The reaction was stopped by the addition of glacial acetic acid (5.2% final concentration) and the amount of pNA released was measured at 405 nm in a 96-well microtiter plate (No. 3075 plates, Falcon Labware, Oxnard, CA) using a Vmax Kinetic Microplate Reader (Molecular Devices, Palo Alto, CA). Factor IXa alone had no amidolytic activity against S2337. From a calibration curve made with known amounts of factor Xa under the same conditions as described above, the amount of factor Xa present in the aliquot was calculated. The rates of factor Xa formation in the reaction mixture were calculated from the amounts of factor Xa present in the samples. The amount of factor IXa present in the incubation mixture was chosen such that < 10% of added factor X was converted to factor Xa during the time course of the experiment.
Calculation ofkinetic constants. The derivation ofkinetic constants for factor X activation by factor IXa was based on a one-enzyme, one-substrate model. Values for the Michaelis constant (Km) and the maximum velocity (Vn.) were calculated from the mean±standard error of the mean of three independent determinations by the Lineweaver-Burk method (22) and were calculated by using least-squares fit and the FORTRAN program ofCleland (23) (24, 25) that take into account a reduction in factor IXa concentration through its binding to receptor.
Results and Discussion
We have previously demonstrated that 125I-labeled factor IXa binds in a saturable and reversible manner to thrombin-acti- (Fig. 1 A) . Table I ).
In this study we also determined an apparent 14 for factor IXa binding by kinetic studies of factor Xa formation in the presence of saturating factor X and factor VIlla (Fig. 1 B) . The kinetic approach gave similar results to the binding studies (13) and its use is justified under Methods. Hence, kinetic studies were performed in the presence of saturating levels of factor X and factor Vllla. The apparent Kd was determined as 0.52 nM for normal platelets and 2.5 nM for Scott syndrome platelets, indicating again that the affinity of the patient platelets for factor IXa was not enhanced by factor X and factor VIlla ( Fig. 1 B and Table I) .
We also determined the kinetic parameters for factor X activation by factor IXa in the presence of normal or patient platelets either in the absence (Fig. 2 A) or presence ( Fig. 2 B) of thrombin-activated factor VIII. Studies were performed at a factor IXa concentration of 0.01 nM, which is well below the apparent dissociation constant for binding of factor IXa to normal or patient platelets. In the absence of factor VIIIa, the Km and kCat were almost identical for normal and patient platelets (Table I ). In contrast, in the presence of saturating concentrations of factor VIIIa, while the Km for patient platelets decreased from 0.5 to 0.11 ,uM in a manner comparable to normal platelets, the kCat for the patient's platelets (163 min-') was only 33% of that for normal platelets (491 min-' Rates of factor Xa formation by factor IXa in the presence of thrombin-activated platelets and factor VIlla. The rate of activation of human factor X by varying concentrations (0.17-3.5 nM) of factor IXa was determined in the presence of 5 X 107/ml stimulated platelets in 37°C in a reaction volume of 100 I containing 50 mM Tris (pH 7.9), 175 mM NaCl, 5 mM CaC12, 1.5 AM factor X, 5 U/ml of factor VIII, and 0.5 mg/ml human serum albumin. Platelets were stimulated with 0.1 U/ml thrombin in the presence of CaCl2 (5 mM), and factor IXa was preincubated with platelets for 10 min at 37°C. Excess actually observed. By this reasoning, the rates of factor Xa divided by the amounts of factor IXa bound (in picomoles per formation by both normal and patient platelets should be 109 platelets, Fig. 1 A) . The resulting turnover numbers (in identical when the factor IXa site is saturated. This is borne moles of factor Xa formed per mole of factor IXa bound per out by the data in Fig. 1 B that shows the same rate of factor minute) were independent of enzyme concentration, as they Xa formation by normal and patient platelets as factor IXa should be at saturating substrate concentration. Furthermore, approaches saturation. Moreover, we have actually calculated the mean (±SEM, n = 5) value for normal platelets was 2,280 the turnover numbers for factor X activation by factor IXa (±138), compared with 2,361 (±88) for Scott syndrome platebound to normal or patient platelets from the data presented lets.
in Fig. 1 A and B. Thus, at five different concentrations of Our studies were carried out at a single concentration of added factor IXa (0.44-3.5 nM) the rates of factor Xa formed factor VIIIa (5 U/ml), which is near the plasma concentration (in picomoles per 109 platelets per minute, Fig. 1 B) were of factor VIII. This concentration of factor VIII has been formation by factor IXa in the pres-FX ADDED (pM) FX ADDED (nM) ence of thrombin-activated platelets and factor VIlla. Thrombin-stimulated (0.1 U/ml), gel-filtered platelets (5 X 107/ml) were preincubated with factor IXa (0.01 nM) and 5 mM CaCl2 at 37°C for 10 min and with 50 mM PPACK for 2 min at 37°C prior to addition to a reaction mixture containing 50 mM Tris-HCI, 175 mM NaCl, 0.5 mg/ml human serum albumin (pH 7.9), factor VIIIa (5 U/ml final concentration separately incubated at 37°C for 1 min at a concentration of 210 U/ml with 0.01 U/ml thrombin before addition to a reaction mixture) and various concentration of factor X (0.075-2 ,M). The details are described in Methods. The results presented are the means±SEM of duplicate observations with platelets from three separate normal donors (e) and means of duplicate observations with MS platelets (A).
shown to be saturating for normal platelets (14) and saturating in our own experiments of factor IXa binding (13) and factor X activation (this paper). It remains to be seen what the effect of higher or lower concentrations of factor VIlla will have on the differences observed between normal and Scott syndrome platelets. We conclude that the major difference between normal and Scott syndrome platelets lies in the ability of factor VIIIa, alone or in combination with factor X, to enhance factor IXa binding to normal but not patient platelets to give a more active form of factor IXa. This result suggests the possibility of an impairment of factor VIIIa binding or a diminished affinity of the factor VIlla-IXa complex for Scott syndrome platelets in the presence of factor X. These possibilities will be examined by direct factor VIIIa binding studies to Scott syndrome platelets.
